Contineum Therapeutics, Inc. Class A (CTNM) AI Stock Analysis

• Market Cap: $138.93M
• Dividend Yield: N/A
• Average Volume (3M): 54.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: -100.00%
• EPS Growth: -244.85%
• Country: US
• Employees: 41
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -1.64
• Shares Outstanding: 19,142,378
• 10 Day Avg. Volume: 56,334
• 30 Day Avg. Volume: 54,227
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $23.75
• Price Target Upside: 395.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Contineum Therapeutics, Inc. is facing significant financial and operational challenges, primarily due to a lack of revenue generation and negative profitability. Technical indicators suggest bearish momentum, which, coupled with a poor valuation, results in a low overall stock score. The company's strong cash reserves and debt reduction are positive factors but are overshadowed by substantial financial risks.

Positive Factors

Financial Position

A strong cash position of $219M will support multiple clinical readouts.

Market Opportunity

IPF opportunity appears undervalued. IPF is a multibillion dollar market with clear unmet needs that a potential best-in-class LPA1RA like PIPE-791 can address.

Product Efficacy

PIPE-791 appears likely to show best-in-class efficacy/safety, which could make it the leading LPA1RA, despite BMS' potential first-to-market advantage.

Negative Factors

Product Limitation

Success with PIPE-791 in idiopathic pulmonary fibrosis does not necessarily improve chances in primary-progressive multiple sclerosis due to the need for organ-specific bioavailability data.

Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

How the Company Makes Money

Contineum Therapeutics, Inc. generates revenue through the successful development and commercialization of its drug candidates. The company primarily makes money by licensing its proprietary technologies and therapies to larger pharmaceutical companies in exchange for upfront payments, milestone payments, and royalties on sales. Additionally, Contineum may receive funding through research grants and collaborations with academic institutions or other biopharmaceutical companies. The company's earnings are further supported by strategic partnerships that provide financial backing and resources to accelerate the development process, ultimately contributing to its financial growth and sustainability.

Contineum Therapeutics, Inc. Class A Financial Statement Overview

Summary

Contineum Therapeutics, Inc. faces significant financial challenges, particularly in generating revenue and maintaining profitability. While debt reduction and strong cash reserves are positive, the negative equity and cash flow issues require strategic focus to ensure long-term viability. The company's financial health is under pressure, demanding careful management and potential restructuring efforts.

Income Statement

Contineum Therapeutics, Inc. shows a challenging income statement with no revenue in the latest period, resulting in negative profitability metrics. The company has seen significant fluctuations, with past revenue and subsequent losses. The lack of revenue growth and negative margins indicate significant financial challenges in generating sales or reducing costs.

Balance Sheet

The balance sheet presents a mixed picture. On the positive side, the company has a strong cash position and a significant reduction in total debt, indicating improved financial stability. However, negative stockholders' equity remains a concern, suggesting ongoing financial risks and potential insolvency issues.

Cash Flow

Cash flow analysis reveals a problematic situation with negative operating and free cash flows, although there is a notable improvement in cash generated from financing activities. The negative free cash flow to net income ratio highlights a lack of operational sustainability, posing liquidity challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	50.00M	0.00	0.00
	Gross Profit
0.00	50.00M	-329.00K	0.00
	EBIT
-50.89M	16.08M	-22.72M	-28.65M
	EBITDA
-50.89M	23.57M	-23.54M	-28.34M
	Net Income Common Stockholders
-42.26M	22.72M	-24.25M	-29.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
204.76M	125.19M	47.24M	69.00M
	Total Assets
212.85M	130.39M	50.64M	70.52M
	Total Debt
6.26M	193.19M	138.33M	4.91M
	Net Debt
-15.68M	177.67M	132.76M	279.00K
	Total Liabilities
14.78M	198.32M	143.85M	141.41M
	Stockholders Equity
198.07M	-67.94M	-93.21M	-70.89M
Cash Flow		Free Cash Flow
-33.36M	18.93M	-20.24M	-26.43M
	Operating Cash Flow
-32.84M	19.35M	-20.12M	-26.27M
	Investing Cash Flow
-69.74M	-65.57M	22.30M	-64.97M
	Financing Cash Flow
109.00M	56.18M	-1.24M	79.84M

Contineum Therapeutics, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Negative. The current price of 4.79 is below the 20-day moving average (MA) of 6.73, below the 50-day MA of 7.44, and below the 200-day MA of 14.61, indicating a bearish trend. The MACD of -0.30 indicates Negative momentum. The RSI at 36.99 is Neutral, neither overbought nor oversold. The STOCH value of 15.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTNM.

Contineum Therapeutics, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$63.05B	15.04	15.95%	0.16%	8.27%	10.35%
GILD	75 Outperform	$131.21B	275.16	2.28%	3.00%	6.16%	-91.54%
BIIB	65 Neutral	$17.64B	10.78	10.36%	―	-1.60%	39.71%
VRTX	64 Neutral	$123.99B	―	-3.15%	―	11.64%	-114.72%
Sector *	54 Neutral	$4.01B	-18.30	-14.99%	6.62%	25.52%	-80.16%
ALNY	50 Neutral	$30.30B	―	-414.62%	―	22.97%	38.54%
CTNM	34 Underperform	$138.93M	―	-64.95%	―	-100.00%	-244.85%

Contineum Therapeutics, Inc. Class A Corporate Events

Contineum Therapeutics Appoints Diego Miralles to Board

On March 14, 2025, Contineum Therapeutics, Inc. appointed Diego Miralles, M.D. to its Board of Directors as a Class II director, with his term expiring at the 2026 annual meeting of stockholders. Dr. Miralles, who has extensive experience in the pharmaceutical and biotechnology sectors, was previously engaged with the company under an advisor agreement that provided strategic, scientific, and clinical development consulting services. His appointment is part of the company’s ongoing efforts to strengthen its leadership team. Dr. Miralles will receive compensation as a non-employee director, including an initial grant of stock options, and has entered into an indemnification agreement similar to those of other board members.